Vitamin D status correction in Saudi Arabia: an experts’ consensus under the auspices of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis, and Musculoskeletal Diseases (ESCEO)

• DOI: 10.1007/s11657-016-0295-y
• Publication Date: 2016-12-21T13:23:02Z
• Authors: Nasser M. Al-Daghri; Yousef Al-Saleh; Naji Aljohani; Riad Sulimani; Abdulaziz M. Al-O...; Hanan Alfawaz; Mona Fouda; Fahad Al-Amri; Awad Shahrani; Mohammed Alharbi; Fahad Alshahrani; Waleed Tamimi; Shaun Sabico; Rene Rizzoli; Jean-Yves Reginster
• Keywords: ddc:616; Saudi Arabia; Disease Management; Vitamins; Vitamin D Deficiency; 3. Good health; 03 medical and health sciences; 0302 clinical medicine; info:eu-repo/classification/ddc/616; Dietary Supplements; Prevalence; Humans; Orthopedics and Sports Medicine; Position Paper; Vitamin D

Vitamin D deficiency is common in the Middle East and Saudi Arabia, particular. While several international recommendations on management of vitamin have been documented practiced globally, these should be adapted to conditions Eastern region. To address this challenge, Prince Mutaib Chair for Biomarkers Osteoporosis (PMCO) King Saud University (KSU), Riyadh, KSA, together with local experts cooperation European Society Clinical Economic Aspects Osteoarthritis (ESCEO), organized a panel that formulated unified diagnosis treatment The selection commenced during 2nd International Symposium conducted last January 20-–21, 2016. Reviews most recent literature were done, face-to-face meetings revisions final recommendations.Results: sufficiency defined as circulating serum 25(OH)D ≥50 nmol (≥20 ng/ml) general population adequacy >75 nmol/L l (>30 frail osteoporotic elderly. Despite overwhelming prevalence deficiency, universal screening not recommended. Recommendations population, children, pregnant/lactating women, post-menopausal elderly, those subsequent metabolic diseases provided. supplementation/correction advised all persons whose falls below 50 nmol/l (20 ng/ml), achieving target 75 (30 particularly suited frail, osteoporotic, older patients. Conducting well-designed clinical trials region will economic implications investigations persistence compliance are encouraged.